Researchers concluded: “Within six weeks on the therapy, median pain scores decreased significantly. There were no severe adverse events reported.”
“Sublingual CBD was found to be well-tolerated and provided statistically significant improvements in several BPS parameters,” investigators determined.
“Participants reported more energy and vitality [and] also better mental and general health status.”
Despite the lack of impairment, subjects still tested positive for trace levels of THC — potentially putting them at risk of violating certain traffic safety laws.